Background: Approximately one fifth of adults are diagnosed with gallstones worldwide. Of these, around 25% develop gallstone disease (indicated by the presence of symptoms) and undergo cholecystectomy. Summary: The risk of gallstones is influenced by a combination of genetic and lifestyle factors, such as excess body weight. In fact, body mass has been demonstrated to be a major risk factor for symptomatic gallstones. Rapid weight loss can also initiate a prolithogenic state and further increase the likelihood of either gallstone formation or existing gallstones becoming symptomatic; however, sensible weight loss strategies can mitigate this risk. This review discusses the role of excess body weight and the risk of gallstone disease, as well as the options available for the prevention of symptomatic gallstones. Key Messages: Healthy weight loss diets combined with regular physical activity can promote successful weight loss and weight maintenance and reduce the risk of gallstones. Should rapid weight loss be required for health reasons or be expected, e.g., after bariatric surgery, prophylactic ursodeoxycholic acid during the period of weight reduction has been demonstrated to reduce the incidence of gallstones formation or symptomatic gallstone occurrence. The recent German guidelines on gallstones recommend simultaneous cholecystectomy during bariatric surgery but only for those with preexisting symptomatic stones.

The global prevalence of gallstones has been reported to be up to 20% in adults [1]. The identification of gallstones per se does not necessitate treatment, as the majority of individuals with stones remain asymptomatic. However, approximately 25% develop symptoms and/or complications [2, 3] and are therefore diagnosed as having gallstone disease, for which (laparoscopic) cholecystectomy (gallbladder removal) is the gold standard treatment [1].

Gallstones are classified based on their localization (gallbladder or biliary tract) and composition, which is determined by physical-chemical alterations in bile, and differentiated by elevated cholesterol or bilirubin concentrations. Approximately 90% of gallstones are cholesterol stones and primarily composed of cholesterol [4]. The remaining 10% are made up of black and brown pigment stones which are mainly composed of calcium bilirubinate, calcium complexes, and mucin glycoproteins, or unconjugated bilirubin, respectively [4].

The risk of gallstones entails a combination of both nonmodifiable (genetic) and modifiable (environmental/lifestyle) factors. Genetic variants have been determined to account for approximately a quarter of the overall gallstone risk [5]. The most commonly reported genetic risk factor in humans identified in genome-wide association studies is the ABCG8 p.D19H variant of the hepatocanalicular cholesterol transporter, a heterodimer of ATP-binding cassette transporters [6]. Modifiable risks entail a combination of factors such as body weight, parity, metabolic aberrations including obesity, hyperinsulinemia, insulin resistance, and diabetes, or physical inactivity and energy-dense nutrition, including increased consumption of refined carbohydrates and saturated fats and a limited intake of fiber. In addition, certain medications, such as estrogens and progesterone, can predispose to lithogenic states [7]. This review focuses on the modifiable risk and prevention options for gallstones related to obesity in adults.

Increased body weight is an established risk factor for gallstone formation, and indeed an increased BMI has been demonstrated to be causally linked to the risk of symptomatic stones, as illustrated in a mendelian randomization study in 77,679 individuals [8]. This report showed symptomatic gallstones in 5.2% (4,106 individuals) of cases in up to 34 years of follow-up, with the findings being more distinct in women. The distribution of body fat also affects the risk of gallstones, with prospective cohort studies showing an association between gallstone formation and central adiposity as compared to limb or lower-extremity adiposity [9]. The increased risk associated with abdominal adiposity can occur independently of BMI, as illustrated in 2 cohorts from the USA [10, 11]. Both obesity and abdominal obesity increase the risk not only of stone formation but also of requiring surgical treatment (cholecystectomy) because of the higher likelihood of presenting with symptomatic stones [10, 12, 13]. Abdominal adiposity is associated with insulin resistance which, given its stimulating effects on hepatic cholesterol secretion, is reported as a key factor in gallstone formation [14].

The influence of body weight on gallstones has also recently been suggested to occur independently of age. For example, a retrospective cross-sectional Asian study [15] observed participants younger than 50 years to have a higher risk of gallstones (OR = 5.4; 95% CI 2.3–12.7) if they were obese and showed features of the metabolic syndrome. Here, obesity was defined as a BMI >25 for Asians [16]. Features of the metabolic syndrome were defined according to a set of accepted unified criteria [see full details in 17]. Moreover, the prevalence of gallstones in individuals younger than 50 years with obesity and metabolic syndrome was identical to the prevalence of gallstones in elderly people who were metabolically healthy and not obese.

The pathophysiological mechanisms that increase the risk of gallstones with excess body fat are multifactorial. The primary risk is the occurrence of cholesterol gallstones, which result from the accumulation of cholesterol monohydrate crystals precipitating in gallbladder bile containing excess cholesterol as compared to bile salts and phospholipids [18]. This excess cholesterol is secreted by hepatocytes as a direct result of increased body weight. Thus, increased body fat is lithogenic [19], and the higher the body weight, the greater the risk of cholesterol stones in the gallbladder [12]. It has been estimated that each extra kilogram of body fat yields the production of approximately 20 mg of additional cholesterol. This excess cholesterol contributes to the saturation of bile with cholesterol and, accordingly, cholesterol supersaturation of gallbladder bile has been documented in obese patients but not in nonobese controls [20]. Increased body weight is additionally associated with reduced gallbladder motility, another factor that contributes to stone production [21].

More recently, a Chinese study observed higher concentrations of (high-sensitivity) C reactive protein (CRP) to be an independent risk factor for new-onset cholesterol gallstones [22]. Specifically, a high-sensitivity CRP concentration >3 mg/L was associated with a 12% increased risk of stones. Currently, it remains unknown how elevated CRP increases the risk of gallstones; however, it has been suggested as being associated with obesity, where secretion of the proinflammatory cytokine interleukin-6 (an upstream stimulator of CRP production in the liver) is stimulated by adipose tissue and contributes to systemic inflammation in obesity [23, 24].

In general, weight loss reduces the risk of gallstones, with the exception of 2 specific settings: weight loss that is extremely rapid (i.e., >1.5 kg/week) and excessive weight reduction (i.e., >25% body weight) [25-27]. In both of these cases, the risk of gallstones occurring increases [28, 29]. Rapid weight loss can predispose to a lithogenic state and subsequently the formation of gallstones [27]. In addition, weight loss induced after bariatric surgery has been reported to initiate biliary sludge (composed of precipitated lipid particles such as aggregated crystals or microliths) and gallstones in 30% of cases during the 6-month period after receiving a gastric bypass or biliopancreatic diversion [30, 31]. A comparable incidence (30%) of gallstones after sleeve gastrectomy was reported at 6–12 months postsurgery in a prospective study [32]. These risks, however, have not been reported with laparoscopic gastric banding [33].

Weight cycling (i.e., weight that is lost and regained) is an independent risk factor for gallstones [34-36]. Weight fluctuations also increase the risk of requiring a cholecystectomy [35]. Syngal et al. [35] observed both moderate (4.5–8.5 kg) and severe (≥9 kg) fluctuations in a single weight cycle to increase the risk of cholecystectomy by 31 and 68%, respectively. Alterations of the ratio of cholesterol to bile salts within the gallbladder were observed in the setting of weight fluctuations and in rapid weight loss [37], reflecting increased hepatic cholesterol secretion and synthesis as well as a reduced secretion of bile salts [18]. An impairment in gallbladder motility also occurs, which triggers the formation of biliary sludge [37, 38].

The Role of Cholecystectomy

Cholecystectomy is the gold standard treatment for symptomatic gallstones, and it is often but not routinely carried out during bariatric surgery in obese patients. There has been a reduction in the rate of simultaneous cholecystectomies in recent years due to the morbidity and mortality associated with the procedure as well as a high reintervention risk [39]. Studies have reported concomitant cholecystectomy to result in longer operation times, longer hospital stays, and higher complication rates [39, 40]. The risk of secondary cholecystectomy was demonstrated to be 6.8% (with 5.3% of these cases presenting with symptoms) after laparoscopic Roux-en-Y reconstruction, as reported in a meta-analysis of 13 studies, 12 of which were retrospective [41]. Other studies have shown the incidence of cholecystectomy to range from 3.3 and 14.7% in the 6–24 months after bariatric surgery [42, 43]. Generally, the morbidity and mortality for cholecystectomy in obese patients not undergoing bariatric surgery do not appear to be higher than those of the general population [44]. There have been previous reports of increased procedure times and postoperative morbidities in obesity; however, these did not differ significantly compared to non-obese controls [45]. Recently, Reeves et al. [44] reported a small increased odds of hospital admissions in patients with severe morbid obesity (BMI >50) compared to patients with a BMI between 30 and 40, but this increased risk was only modest (OR = 1.10; 95% CI 1.02–1.19; p < 0.001).

As such, the recent German consensus guidelines for gallstone disease recommend simultaneous cholecystectomy only in obese patients with symptomatic gallstones [39, 46], as do the European guidelines [47]. These risks do, however, differ depending on the type of bariatric surgery, with the laparoscopic Roux-en-Y surgery displaying a higher risk than either gastric banding or sleeve resection [48]. Two recent studies corroborated the guideline recommendations; Della Penna et al. [49] followed up 61 patients with asymptomatic gallstones treated with ursodeoxycholic acid (UDCA) for 6 months after bariatric surgery (either laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy). Cholecystectomy was required in 1 patient only who had undergone sleeve gastrectomy. Another patient reported symptoms during the 6-month follow-up after sleeve gastrectomy but did not require cholecystectomy. The remaining 59 patients remained asymptomatic with UDCA prophylaxis.

The Swedish Obese Subjects study [50] also supports the recent guidelines, reporting an overall low cumulative incidence for cholecystectomy after bariatric surgery. This nonrandomized, controlled study compared standard of care with the effects of bariatric surgery [50]. Overall, 3,597 participants who had not undergone previous or concomitant cholecystectomy at the time of inclusion were analyzed. The cohort was divided into 2 groups: 1,755 patients received bariatric surgery (gastric bypass, n = 236; vertical banded gastroplasty, n = 1,202; and gastric banding, n = 317). The control group (n = 1,842) received the usual treatment for obesity, including lifestyle advice. UDCA was not provided to any of the groups. During 26 years of follow-up, modest weight changes were observed in the control group (3% fluctuations), in contrast to the surgical group where weight loss averaged 25% at 2 years and 16% at both 10 and 15 years. Symptomatic gallstone incidence differed significantly (p < 0.001), with the surgery group reporting 307 first-time events versus 252 in the controls. A similar trend was observed for complicated gallstones and the rate of cholecystectomies, with 172 versus 144 first-time events (p < 0.006) and 230 versus 170 cases (p < 0.001), respectively. The above risks were more pronounced during the first 5 years after surgery.

Given the invasiveness of the standard treatment for gallstone disease, a greater emphasis on the prevention of gallstones is required and it is discussed in the following sections within the context of excess body weight.

Diet and Physical Activity

Steady weight reduction (i.e., <1.5 kg/week) is recommended in the setting of obesity and gallstone risks (as discussed in Rapid Weight Loss and Weight Cycling). The increased risks of gallstones have been illustrated with 2 popular weight reduction methods, i.e., bariatric surgery and very low-calorie diets [26-28, 51], with approximate risks of 30 and 25%, respectively [26, 28]. Randomized controlled trials in obese patients have demonstrated these risks to be mitigated to a certain degree when weight loss diets have a higher fat content [37, 52, 53]. General nutrition-related recommendations include reducing the energy density of the diet (particularly avoiding saturated fats and sugar) and instead consuming fiber-rich foods such as wholegrains, fruits, or vegetables [54-59]. Reducing energy-dense foods, particularly those high in sugar, has shown beneficial effects on both weight and gallstone risk [60]. A high dietary glycemic load increases the risk of gallbladder stone formation [61-63]. In contrast, fiber-rich foods reduce the risk of cholecystectomy in women [64, 65]. Additionally, a reduction in the lithogenicity of hydrophobic bile salts was demonstrated with consumption of high-fiber and calcium-rich foods [66]. However, fiber supplementation during weight loss did not lead to significant benefits in terms of gallstone development in a randomized study with obese participants [67]. Other foods reported to reduce the risk of cholecystectomy include legumes, olive oil [68], and nuts [69].

Dietary lipids are mediators of gallstone risk, with unsaturated fatty acids displaying risk reduction properties and saturated and trans fats increasing the risk [70-72]. In patients with gallstones, omega-3 fatty acid supplementation reduced the cholesterol saturation index in bile [73]. Another study in obese women without gallstones who were randomized to receiving omega-3 fatty acids or UDCA or placebo for 6 weeks did not observe a reduction of biliary cholesterol saturation, despite the fact that none of the participants developed gallstones during this intervention period [74]. The omega-3 group did, however, display improved gallbladder motility in patients with hypertriglyceridemia [75]. Additionally, gallbladder hypomotility might be mitigated by reducing the time of overnight fasting to less than 12 h, as suggested by observational data [76].

Physical activity has a multitude of benefits with regard to weight loss and weight maintenance, and it has also been studied for its direct effects on gallstone risk. In fact, several studies have reported physical activity as having protective effects on the formation of gallstones [34, 63, 77-79]. Intervention studies, however, show only modest effects: improvements in gallbladder motility were observed in a randomized study, where the intervention included moderate training, but the results were similar in the control group [80]. A lack of significant effects on gallstones was also reported in pregnant women taking part in a randomized study [81].

Prophylactic Ursodeoxycholic Acid

During the weight reduction phase, prophylactic ursodeoxycholic acid has shown great promise in reducing the formation of gallstones regardless of the method of weight loss, i.e., low-calorie diets or bariatric surgery, with reductions as high as 58% reported in randomized controlled trials [25, 29, 31, 53, 82-85]. A minimum dose of 500 mg/day is recommended, as shown in clinical trials and a meta-analysis of such trials, with this dose being more effective than 300 mg/day in reducing the risk of gallstones forming during a 6-week period but also after 3–4 months [53]. A higher dose has not shown greater benefits either, as illustrated in a randomized trial in patients receiving gastric bypass [31]. In this study, 3 UDCA doses were compared: 300, 600 and 1,200 mg/day for 6 months. The 600-mg dose was the most efficacious at preventing gallstones, with an incidence of 2 versus 13 and 6% in those receiving 300 and 1,200 mg, respectively. These findings have been corroborated [29].

Since subsequent cholecystectomy, e.g. after bariatric surgery, can be performed should gallstones become symptomatic, many patients do not receive prophylactic UCDA during the weight reduction phase in clinical practice [86, 87]. Given the benefits reported above, recent guidelines on gallstones have strongly recommended UDCA be given as a prophylaxis in the case of a high risk of sludge or stone formation when undergoing weight loss either through low-calorie diets or bariatric surgery [46, 47]. Studies suggest the first 6 months after surgery to be the most critical because they are associated with the greatest reduction in body weight, with UDCA showing mild benefits after the first 6 months that do not justify prolonged prophylaxis [88]. A recent randomized study assessed the effects of prophylactic UDCA on the incidence of gallstones in 190 patients undergoing 1 anastomosis gastric bypass [89]. These patients were randomized to either 600 mg/day of oral UDCA (n = 95) or to a control group (n = 95) for 6 months. The incidence of gallstones after 3 months was 0 versus 4 (4.2%) in the UDCA and control groups, respectively, and 3 (3.1%) versus 21 (22.1%) at 6 months. After 12 months of follow-up, 4 (4.2%) versus 24 (25.2%) patients in the UDCA and control groups developed gallstones, respectively (p < 0.05). The majority were asymptomatic, with only 28.6% of participants displaying symptoms. Multivariate analyses identified UDCA as the only significant predictor of gallstone formation (HR = 0.17; 95% CI 0.06–0.48; p < 0.001).

Excess body weight is associated with an increased risk of cholesterol gallstones. As summarized in Figure 1, sensible weight loss strategies can mitigate this risk, but rapid weight loss or weight cycling might trigger a lithogenic cascade and further increase the probability of either gallstones forming or of stones becoming symptomatic. Healthy nutrition with an emphasis on plant foods and unsaturated fats combined with regular physical activity can promote successful weight loss and weight maintenance. In the case of rapid weight loss, such as in the setting of bariatric surgery, prophylactic UDCA during the initial 6 months has been demonstrated to reduce the incidence of both gallstones and biliary symptoms. Such a strategy should benefit patients who are candidates for bariatric surgery or who for other health reasons need to undergo rapid weight loss, since recent guidelines do not recommend simultaneous cholecystectomy during surgery unless the patient has a preexisting diagnosis of symptomatic gallstones.

Fig. 1.

Suggested approach based on clinical evidence and guideline recommendations to reduce the risk of gallstone disease in overweight/obese patients undergoing weight loss.

Fig. 1.

Suggested approach based on clinical evidence and guideline recommendations to reduce the risk of gallstone disease in overweight/obese patients undergoing weight loss.

Close modal

The authors of the present review have nothing to declare.

No funding was received for the preparation of this review.

Both of the authors drafted and revised this paper.

1.
Everhart
JE
,
Ruhl
CE
.
Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas
.
Gastroenterology
.
2009
Apr
;
136
(
4
):
1134
44
.
[PubMed]
0016-5085
2.
Portincasa
P
,
Ciaula
AD
,
Bonfrate
L
,
Wang
DQ
.
Therapy of gallstone disease: what it was, what it is, what it will be
.
World J Gastrointest Pharmacol Ther
.
2012
Apr
;
3
(
2
):
7
20
.
[PubMed]
2150-5349
3.
Attili
AF
,
De Santis
A
,
Capri
R
,
Repice
AM
,
Maselli
S
,
Group
G
;
The GREPCO Group
.
The natural history of gallstones: the GREPCO experience
.
Hepatology
.
1995
Mar
;
21
(
3
):
655
60
.
[PubMed]
0270-9139
4.
Schafmayer
C
,
Hartleb
J
,
Tepel
J
,
Albers
S
,
Freitag
S
,
Völzke
H
, et al
Predictors of gallstone composition in 1025 symptomatic gallstones from Northern Germany
.
BMC Gastroenterol
.
2006
Nov
;
6
(
1
):
36
.
[PubMed]
1471-230X
5.
Katsika
D
,
Grjibovski
A
,
Einarsson
C
,
Lammert
F
,
Lichtenstein
P
,
Marschall
HU
.
Genetic and environmental influences on symptomatic gallstone disease: a Swedish study of 43,141 twin pairs
.
Hepatology
.
2005
May
;
41
(
5
):
1138
43
.
[PubMed]
0270-9139
6.
Lammert
F
,
Sauerbruch
T
.
Mechanisms of disease: the genetic epidemiology of gallbladder stones
.
Nat Clin Pract Gastroenterol Hepatol
.
2005
Sep
;
2
(
9
):
423
33
.
[PubMed]
1743-4378
7.
Lammert
F
,
Gurusamy
K
,
Ko
CW
,
Miquel
JF
,
Méndez-Sánchez
N
,
Portincasa
P
, et al
Gallstones
.
Nat Rev Dis Primers
.
2016
Apr
;
2
(
1
):
16024
.
[PubMed]
2056-676X
8.
Stender
S
,
Nordestgaard
BG
,
Tybjaerg-Hansen
A
.
Elevated body mass index as a causal risk factor for symptomatic gallstone disease: a Mendelian randomization study
.
Hepatology
.
2013
Dec
;
58
(
6
):
2133
41
.
[PubMed]
0270-9139
9.
Haffner
SM
,
Diehl
AK
,
Stern
MP
,
Hazuda
HP
.
Central adiposity and gallbladder disease in Mexican Americans
.
Am J Epidemiol
.
1989
Mar
;
129
(
3
):
587
95
.
[PubMed]
0002-9262
10.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Central adiposity, regional fat distribution, and the risk of cholecystectomy in women
.
Gut
.
2006
May
;
55
(
5
):
708
14
.
[PubMed]
0017-5749
11.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Prospective study of abdominal adiposity and gallstone disease in US men
.
Am J Clin Nutr
.
2004
Jul
;
80
(
1
):
38
44
.
[PubMed]
0002-9165
12.
Maclure
KM
,
Hayes
KC
,
Colditz
GA
,
Stampfer
MJ
,
Speizer
FE
,
Willett
WC
.
Weight, diet, and the risk of symptomatic gallstones in middle-aged women
.
N Engl J Med
.
1989
Aug
;
321
(
9
):
563
9
.
[PubMed]
0028-4793
13.
Völzke
H
,
Baumeister
SE
,
Alte
D
,
Hoffmann
W
,
Schwahn
C
,
Simon
P
, et al
Independent risk factors for gallstone formation in a region with high cholelithiasis prevalence
.
Digestion
.
2005
;
71
(
2
):
97
105
.
[PubMed]
0012-2823
14.
Nakeeb
A
,
Comuzzie
AG
,
Al-Azzawi
H
,
Sonnenberg
GE
,
Kissebah
AH
,
Pitt
HA
.
Insulin resistance causes human gallbladder dysmotility
.
J Gastrointest Surg
.
2006
Jul-Aug
;
10
(
7
):
940
8
.
[PubMed]
1091-255X
15.
Su
PY
,
Hsu
YC
,
Cheng
YF
,
Kor
CT
,
Su
WW
.
Strong association between metabolically-abnormal obesity and gallstone disease in adults under 50 years
.
BMC Gastroenterol
.
2019
Jul
;
19
(
1
):
117
.
[PubMed]
1471-230X
16.
WHO/IASO/IOTF
.
The Asia-Pacific perspective: redefining obesity and its treatment
.
Melbourne
:
Health Communications Australia
;
2000
.
17.
Alberti
KG
,
Eckel
RH
,
Grundy
SM
,
Zimmet
PZ
,
Cleeman
JI
,
Donato
KA
, et al;
International Diabetes Federation Task Force on Epidemiology and Prevention
;
Hational Heart, Lung, and Blood Institute
;
American Heart Association
;
World Heart Federation
;
International Atherosclerosis Society
;
International Association for the Study of Obesity
.
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
.
Circulation
.
2009
Oct
;
120
(
16
):
1640
5
.
[PubMed]
0009-7322
18.
Portincasa
P
,
Moschetta
A
,
Palasciano
G
.
Cholesterol gallstone disease
.
Lancet
.
2006
Jul
;
368
(
9531
):
230
9
.
[PubMed]
0140-6736
19.
Sahi
T
,
Paffenbarger
RS
 Jr
,
Hsieh
CC
,
Lee
IM
.
Body mass index, cigarette smoking, and other characteristics as predictors of self-reported, physician-diagnosed gallbladder disease in male college alumni
.
Am J Epidemiol
.
1998
Apr
;
147
(
7
):
644
51
.
[PubMed]
0002-9262
20.
Freeman
JB
,
Meyer
PD
,
Printen
KJ
,
Mason
EE
,
DenBesten
L
.
Analysis of gallbladder bile in morbid obesity
.
Am J Surg
.
1975
Feb
;
129
(
2
):
163
6
.
[PubMed]
0002-9610
21.
Di Ciaula
A
,
Wang
DQ
,
Portincasa
P
.
Gallbladder and gastric motility in obese newborns, pre-adolescents and adults
.
J Gastroenterol Hepatol
.
2012
Aug
;
27
(
8
):
1298
305
.
[PubMed]
0815-9319
22.
Liu
T
,
Siyin
ST
,
Yao
N
,
Duan
N
,
Xu
G
,
Li
W
, et al
Relationship between high-sensitivity C reactive protein and the risk of gallstone disease: results from the Kailuan cohort study
.
BMJ Open
.
2020
Sep
;
10
(
9
):
e035880
.
[PubMed]
2044-6055
23.
Kwaifa
IK
,
Bahari
H
,
Yong
YK
,
Noor
SM
.
Endothelial Dysfunction in Obesity-Induced Inflammation: Molecular Mechanisms and Clinical Implications
.
Biomolecules
.
2020
Feb
;
10
(
2
):
291
.
[PubMed]
2218-273X
24.
Cozma
A
,
Orăşan
O
,
Sâmpelean
D
,
Fodor
A
,
Vlad
C
,
Negrean
V
, et al
Endothelial dysfunction in metabolic syndrome
.
Rom J Intern Med
.
2009
;
47
(
2
):
133
40
.
[PubMed]
1220-4749
25.
Broomfield
PH
,
Chopra
R
,
Sheinbaum
RC
,
Bonorris
GG
,
Silverman
A
,
Schoenfield
LJ
, et al
Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight
.
N Engl J Med
.
1988
Dec
;
319
(
24
):
1567
72
.
[PubMed]
0028-4793
26.
Liddle
RA
,
Goldstein
RB
,
Saxton
J
.
Gallstone formation during weight-reduction dieting
.
Arch Intern Med
.
1989
Aug
;
149
(
8
):
1750
3
.
[PubMed]
0003-9926
27.
Weinsier
RL
,
Wilson
LJ
,
Lee
J
.
Medically safe rate of weight loss for the treatment of obesity: a guideline based on risk of gallstone formation
.
Am J Med
.
1995
Feb
;
98
(
2
):
115
7
.
[PubMed]
0002-9343
28.
Li
VK
,
Pulido
N
,
Fajnwaks
P
,
Szomstein
S
,
Rosenthal
R
,
Martinez-Duartez
P
.
Predictors of gallstone formation after bariatric surgery: a multivariate analysis of risk factors comparing gastric bypass, gastric banding, and sleeve gastrectomy
.
Surg Endosc
.
2009
Jul
;
23
(
7
):
1640
4
.
[PubMed]
0930-2794
29.
Shiffman
ML
,
Kaplan
GD
,
Brinkman-Kaplan
V
,
Vickers
FF
.
Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program
.
Ann Intern Med
.
1995
Jun
;
122
(
12
):
899
905
.
[PubMed]
0003-4819
30.
Shiffman
ML
,
Sugerman
HJ
,
Kellum
JH
,
Brewer
WH
,
Moore
EW
.
Gallstones in patients with morbid obesity. Relationship to body weight, weight loss and gallbladder bile cholesterol solubility
.
Int J Obes Relat Metab Disord
.
1993
Mar
;
17
(
3
):
153
8
.
[PubMed]
31.
Sugerman
HJ
,
Brewer
WH
,
Shiffman
ML
,
Brolin
RE
,
Fobi
MA
,
Linner
JH
, et al
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss
.
Am J Surg
.
1995
Jan
;
169
(
1
):
91
6
.
[PubMed]
0002-9610
32.
Adams
LB
,
Chang
C
,
Pope
J
,
Kim
Y
,
Liu
P
,
Yates
A
.
Randomized, Prospective Comparison of Ursodeoxycholic Acid for the Prevention of Gallstones after Sleeve Gastrectomy
.
Obes Surg
.
2016
May
;
26
(
5
):
990
4
.
[PubMed]
0960-8923
33.
O’Brien
PE
,
Dixon
JB
.
A rational approach to cholelithiasis in bariatric surgery: its application to the laparoscopically placed adjustable gastric band
.
Arch Surg
.
2003
Aug
;
138
(
8
):
908
12
.
[PubMed]
0004-0010
34.
Ortega
RM
,
Fernández-Azuela
M
,
Encinas-Sotillos
A
,
Andrés
P
,
López-Sobaler
AM
.
Differences in diet and food habits between patients with gallstones and controls
.
J Am Coll Nutr
.
1997
Feb
;
16
(
1
):
88
95
.
[PubMed]
0731-5724
35.
Syngal
S
,
Coakley
EH
,
Willett
WC
,
Byers
T
,
Williamson
DF
,
Colditz
GA
.
Long-term weight patterns and risk for cholecystectomy in women
.
Ann Intern Med
.
1999
Mar
;
130
(
6
):
471
7
.
[PubMed]
0003-4819
36.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Weight cycling and risk of gallstone disease in men
.
Arch Intern Med
.
2006
Nov
;
166
(
21
):
2369
74
.
[PubMed]
0003-9926
37.
Gebhard
RL
,
Prigge
WF
,
Ansel
HJ
,
Schlasner
L
,
Ketover
SR
,
Sande
D
, et al
The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss
.
Hepatology
.
1996
Sep
;
24
(
3
):
544
8
.
[PubMed]
0270-9139
38.
Shiffman
ML
,
Sugerman
HJ
,
Kellum
JM
,
Moore
EW
.
Changes in gallbladder bile composition following gallstone formation and weight reduction
.
Gastroenterology
.
1992
Jul
;
103
(
1
):
214
21
.
[PubMed]
0016-5085
39.
Worni
M
,
Guller
U
,
Shah
A
,
Gandhi
M
,
Shah
J
,
Rajgor
D
, et al
Cholecystectomy concomitant with laparoscopic gastric bypass: a trend analysis of the nationwide inpatient sample from 2001 to 2008
.
Obes Surg
.
2012
Feb
;
22
(
2
):
220
9
.
[PubMed]
0960-8923
40.
Hamad
GG
,
Ikramuddin
S
,
Gourash
WF
,
Schauer
PR
.
Elective cholecystectomy during laparoscopic Roux-en-Y gastric bypass: is it worth the wait?
Obes Surg
.
2003
Feb
;
13
(
1
):
76
81
.
[PubMed]
0960-8923
41.
Warschkow
R
,
Tarantino
I
,
Ukegjini
K
,
Beutner
U
,
Güller
U
,
Schmied
BM
, et al
Concomitant cholecystectomy during laparoscopic Roux-en-Y gastric bypass in obese patients is not justified: a meta-analysis
.
Obes Surg
.
2013
Mar
;
23
(
3
):
397
407
.
[PubMed]
0960-8923
42.
Kim
JJ
,
Schirmer
B
.
Safety and efficacy of simultaneous cholecystectomy at Roux-en-Y gastric bypass
.
Surg Obes Relat Dis
.
2009
Jan-Feb
;
5
(
1
):
48
53
.
[PubMed]
1550-7289
43.
Swartz
DE
,
Felix
EL
.
Elective cholecystectomy after Roux-en-Y gastric bypass: why should asymptomatic gallstones be treated differently in morbidly obese patients?
Surg Obes Relat Dis
.
2005
Nov-Dec
;
1
(
6
):
555
60
.
[PubMed]
1550-7289
44.
Reeves
JJ
,
Burton
BN
,
Broderick
RC
, et al
Obesity and unanticipated hospital admission following outpatient laparoscopic cholecystectomy
.
Surg Endosc
.
2020
;
•••
:
[PubMed]
0930-2794
45.
Ammori
BJ
,
Vezakis
A
,
Davides
D
,
Martin
IG
,
Larvin
M
,
McMahon
MJ
.
Laparoscopic cholecystectomy in morbidly obese patients
.
Surg Endosc
.
2001
Nov
;
15
(
11
):
1336
9
.
[PubMed]
0930-2794
46.
Gutt
C
,
Jenssen
C
,
Barreiros
AP
,
Götze
TO
,
Stokes
CS
,
Jansen
PL
, et al;
für die Teilnehmer der Konsensuskonferenz
;
Deutsche Gesellschaft für Innere Medizin e.V. (DGIM)
;
Österreichische Gesellschaft für Gastroenterologie und Hepatologie (ÖGGH)
;
Schweizer Gesellschaft für Gastroenterologie (SGH)
;
Gesellschaft für Humangenetik (GfH)
;
Deutsche Gesellschaft für Ultraschall in der Medizin (DEGUM)
;
Deutsche Gesellschaft für Chirurgie (DGCH)
;
Institut für Qualitätssicherung und Transparenz im Gesundheitswesen (IQTIG; beratende Funktion ohne Stimmrecht)
;
Deutsche Arbeitsgemeinschaft zum Studium der Leber (GASL)
;
Deutsche Röntgengesellschaft (DRG)
;
Deutsche Leberhilfe e. V.
[Updated S3-Guideline for Prophylaxis, Diagnosis and Treatment of Gallstones. German Society for Digestive and Metabolic Diseases (DGVS) and German Society for Surgery of the Alimentary Tract (DGAV) - AWMF Registry 021/008]
.
Z Gastroenterol
.
2018
Aug
;
56
(
8
):
912
66
.
[PubMed]
1439-7803
47.
European Association for the Study of the Liver (EASL). Electronic address: easloffice@easloffice.eu
.
EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones
.
J Hepatol
.
2016
Jul
;
65
(
1
):
146
81
.
[PubMed]
0168-8278
48.
Tsirline
VB
,
Keilani
ZM
,
El Djouzi
S
,
Phillips
RC
,
Kuwada
TS
,
Gersin
K
, et al
How frequently and when do patients undergo cholecystectomy after bariatric surgery?
Surg Obes Relat Dis
.
2014
Mar-Apr
;
10
(
2
):
313
21
.
[PubMed]
1550-7289
49.
Della Penna
A
,
Lange
J
,
Hilbert
J
,
Archid
R
,
Königsrainer
A
,
Quante
M
.
Ursodeoxycholic Acid for 6 Months After Bariatric Surgery Is Impacting Gallstone Associated Morbidity in Patients with Preoperative Asymptomatic Gallstones
.
Obes Surg
.
2019
Apr
;
29
(
4
):
1216
21
.
[PubMed]
0960-8923
50.
Anveden
Å
,
Peltonen
M
,
Näslund
I
,
Torgerson
J
,
Carlsson
LM
.
Long-term incidence of gallstone disease after bariatric surgery: results from the nonrandomized controlled Swedish Obese Subjects study
.
Surg Obes Relat Dis
.
2020
Oct
;
16
(
10
):
1474
82
.
[PubMed]
1550-7289
51.
Kamrath
RO
,
Plummer
LJ
,
Sadur
CN
,
Adler
MA
,
Strader
WJ
,
Young
RL
, et al
Cholelithiasis in patients treated with a very-low-calorie diet
.
Am J Clin Nutr
.
1992
Jul
;
56
(
1
Suppl
):
255S
7S
.
[PubMed]
0002-9165
52.
Festi
D
,
Colecchia
A
,
Orsini
M
,
Sangermano
A
,
Sottili
S
,
Simoni
P
, et al
Gallbladder motility and gallstone formation in obese patients following very low calorie diets. Use it (fat) to lose it (well)
.
Int J Obes Relat Metab Disord
.
1998
Jun
;
22
(
6
):
592
600
.
[PubMed]
53.
Stokes
CS
,
Gluud
LL
,
Casper
M
,
Lammert
F
.
Ursodeoxycholic acid and diets higher in fat prevent gallbladder stones during weight loss: a meta-analysis of randomized controlled trials
.
Clin Gastroenterol Hepatol
.
2014
Jul
;
12
(
7
):
1090
1100.e2
.
[PubMed]
1542-3565
54.
Malik
VS
,
Schulze
MB
,
Hu
FB
.
Intake of sugar-sweetened beverages and weight gain: a systematic review
.
Am J Clin Nutr
.
2006
Aug
;
84
(
2
):
274
88
.
[PubMed]
0002-9165
55.
Vartanian
LR
,
Schwartz
MB
,
Brownell
KD
.
Effects of soft drink consumption on nutrition and health: a systematic review and meta-analysis
.
Am J Public Health
.
2007
Apr
;
97
(
4
):
667
75
.
[PubMed]
0090-0036
56.
Harland
JI
,
Garton
LE
.
Whole-grain intake as a marker of healthy body weight and adiposity
.
Public Health Nutr
.
2008
Jun
;
11
(
6
):
554
63
.
[PubMed]
1368-9800
57.
Savage
JS
,
Marini
M
,
Birch
LL
.
Dietary energy density predicts women’s weight change over 6 y
.
Am J Clin Nutr
.
2008
Sep
;
88
(
3
):
677
84
.
[PubMed]
0002-9165
58.
Bes-Rastrollo
M
,
van Dam
RM
,
Martinez-Gonzalez
MA
,
Li
TY
,
Sampson
LL
,
Hu
FB
.
Prospective study of dietary energy density and weight gain in women
.
Am J Clin Nutr
.
2008
Sep
;
88
(
3
):
769
77
.
[PubMed]
0002-9165
59.
Hooper
L
,
Abdelhamid
A
,
Moore
HJ
,
Douthwaite
W
,
Skeaff
CM
,
Summerbell
CD
.
Effect of reducing total fat intake on body weight: systematic review and meta-analysis of randomised controlled trials and cohort studies
.
BMJ
.
2012
Dec
;
345
dec06 1
:
e7666
.
[PubMed]
0959-8138
60.
Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF Online). Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas“.
2014
, Registernummer 050 - 001. Deutsche Adipositas-Gesellschaft (DAG) e.V., Deutsche Diabetes Gesellschaft (DDG), Deutsche Gesellschaft für Ernährung (DGE) e.V., Deutsche Gesellschaft für Ernährungsmedizin (DGEM) e.V.
61.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Glycemic load, glycemic index, and carbohydrate intake in relation to risk of cholecystectomy in women
.
Gastroenterology
.
2005
Jul
;
129
(
1
):
105
12
.
[PubMed]
0016-5085
62.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Dietary carbohydrates and glycaemic load and the incidence of symptomatic gall stone disease in men
.
Gut
.
2005
Jun
;
54
(
6
):
823
8
.
[PubMed]
0017-5749
63.
Misciagna
G
,
Centonze
S
,
Leoci
C
,
Guerra
V
,
Cisternino
AM
,
Ceo
R
, et al
Diet, physical activity, and gallstones—a population-based, case-control study in southern Italy
.
Am J Clin Nutr
.
1999
Jan
;
69
(
1
):
120
6
.
[PubMed]
0002-9165
64.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Fruit and vegetable consumption and risk of cholecystectomy in women
.
Am J Med
.
2006
Sep
;
119
(
9
):
760
7
.
[PubMed]
0002-9343
65.
Nordenvall
C
,
Oskarsson
V
,
Wolk
A
.
Fruit and vegetable consumption and risk of cholecystectomy: a prospective cohort study of women and men
.
Eur J Nutr
.
2018
Feb
;
57
(
1
):
75
81
.
[PubMed]
1436-6207
66.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Long-term intake of dietary fiber and decreased risk of cholecystectomy in women
.
Am J Gastroenterol
.
2004
Jul
;
99
(
7
):
1364
70
.
[PubMed]
0002-9270
67.
Morán
S
,
Milke
P
,
Rodríguez-Leal
G
,
Uribe
M
.
Ref: gallstone formation in obese subjects undergoing a weight reduction diet
.
Int J Obes Relat Metab Disord
.
1998
Mar
;
22
(
3
):
282
4
.
[PubMed]
68.
Barré
A
,
Gusto
G
,
Cadeau
C
,
Carbonnel
F
,
Boutron-Ruault
MC
.
Diet and risk of cholecystectomy: a prospective study based on the French E3N cohort
.
Am J Gastroenterol
.
2017
Sep
;
112
(
9
):
1448
56
.
[PubMed]
0002-9270
69.
Tsai
CJ
,
Leitzmann
MF
,
Hu
FB
,
Willett
WC
,
Giovannucci
EL
.
Frequent nut consumption and decreased risk of cholecystectomy in women
.
Am J Clin Nutr
.
2004
Jul
;
80
(
1
):
76
81
.
[PubMed]
0002-9165
70.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
The effect of long-term intake of cis unsaturated fats on the risk for gallstone disease in men: a prospective cohort study
.
Ann Intern Med
.
2004
Oct
;
141
(
7
):
514
22
.
[PubMed]
0003-4819
71.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Long-term intake of trans-fatty acids and risk of gallstone disease in men
.
Arch Intern Med
.
2005
May
;
165
(
9
):
1011
5
.
[PubMed]
0003-9926
72.
Tsai
CJ
,
Leitzmann
MF
,
Willett
WC
,
Giovannucci
EL
.
Long-chain saturated fatty acids consumption and risk of gallstone disease among men
.
Ann Surg
.
2008
Jan
;
247
(
1
):
95
103
.
[PubMed]
0003-4932
73.
Berr
F
,
Holl
J
,
Jüngst
D
,
Fischer
S
,
Richter
WO
,
Seifferth
B
, et al
Dietary N-3 polyunsaturated fatty acids decrease biliary cholesterol saturation in gallstone disease
.
Hepatology
.
1992
Oct
;
16
(
4
):
960
7
.
[PubMed]
0270-9139
74.
Méndez-Sánchez
N
,
González
V
,
Aguayo
P
,
Sánchez
JM
,
Tanimoto
MA
,
Elizondo
J
, et al
Fish oil (n-3) polyunsaturated fatty acids beneficially affect biliary cholesterol nucleation time in obese women losing weight
.
J Nutr
.
2001
Sep
;
131
(
9
):
2300
3
.
[PubMed]
0022-3166
75.
Jonkers
IJ
,
Smelt
AH
,
Ledeboer
M
,
Hollum
ME
,
Biemond
I
,
Kuipers
F
, et al
Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil
.
Gut
.
2003
Jan
;
52
(
1
):
109
15
.
[PubMed]
0017-5749
76.
Attili
AF
,
Scafato
E
,
Marchioli
R
,
Marfisi
RM
,
Festi
D
.
Diet and gallstones in Italy: the cross-sectional MICOL results
.
Hepatology
.
1998
Jun
;
27
(
6
):
1492
8
.
[PubMed]
0270-9139
77.
Leitzmann
MF
,
Giovannucci
EL
,
Rimm
EB
,
Stampfer
MJ
,
Spiegelman
D
,
Wing
AL
, et al
The relation of physical activity to risk for symptomatic gallstone disease in men
.
Ann Intern Med
.
1998
Mar
;
128
(
6
):
417
25
.
[PubMed]
0003-4819
78.
Leitzmann
MF
,
Rimm
EB
,
Willett
WC
,
Spiegelman
D
,
Grodstein
F
,
Stampfer
MJ
, et al
Recreational physical activity and the risk of cholecystectomy in women
.
N Engl J Med
.
1999
Sep
;
341
(
11
):
777
84
.
[PubMed]
0028-4793
79.
Storti
KL
,
Brach
JS
,
FitzGerald
SJ
,
Zmuda
JM
,
Cauley
JA
,
Kriska
AM
.
Physical activity and decreased risk of clinical gallstone disease among post-menopausal women
.
Prev Med
.
2005
Sep-Oct
;
41
(
3-4
):
772
7
.
[PubMed]
0091-7435
80.
Utter
AC
,
Whitcomb
DC
,
Nieman
DC
,
Butterworth
DE
,
Vermillion
SS
.
Effects of exercise training on gallbladder function in an obese female population
.
Med Sci Sports Exerc
.
2000
Jan
;
32
(
1
):
41
5
.
[PubMed]
0195-9131
81.
Ko
CW
,
Napolitano
PG
,
Lee
SP
,
Schulte
SD
,
Ciol
MA
,
Beresford
SA
.
Physical activity, maternal metabolic measures, and the incidence of gallbladder sludge or stones during pregnancy: a randomized trial
.
Am J Perinatol
.
2014
Jan
;
31
(
1
):
39
48
.
[PubMed]
1098-8785
82.
Williams
C
,
Gowan
R
,
Perey
BJ
.
A double-blind placebo-controlled trial of ursodeoxycholic acid in the prevention of gallstones during weight loss after vertical banded gastroplasty
.
Obes Surg
.
1993
Aug
;
3
(
3
):
257
9
.
[PubMed]
0960-8923
83.
Worobetz
LJ
,
Inglis
FG
,
Shaffer
EA
.
The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss
.
Am J Gastroenterol
.
1993
Oct
;
88
(
10
):
1705
10
.
[PubMed]
0002-9270
84.
Wudel
LJ
 Jr
,
Wright
JK
,
Debelak
JP
,
Allos
TM
,
Shyr
Y
,
Chapman
WC
.
Prevention of gallstone formation in morbidly obese patients undergoing rapid weight loss: results of a randomized controlled pilot study
.
J Surg Res
.
2002
Jan
;
102
(
1
):
50
6
.
[PubMed]
0022-4804
85.
Miller
K
,
Hell
E
,
Lang
B
,
Lengauer
E
.
Gallstone formation prophylaxis after gastric restrictive procedures for weight loss: a randomized double-blind placebo-controlled trial
.
Ann Surg
.
2003
Nov
;
238
(
5
):
697
702
.
[PubMed]
0003-4932
86.
Villegas
L
,
Schneider
B
,
Provost
D
,
Chang
C
,
Scott
D
,
Sims
T
, et al
Is routine cholecystectomy required during laparoscopic gastric bypass?
Obes Surg
.
2004
Feb
;
14
(
2
):
206
11
.
[PubMed]
0960-8923
87.
Ellner
SJ
,
Myers
TT
,
Piorkowski
JR
,
Mavanur
AA
,
Barba
CA
.
Routine cholecystectomy is not mandatory during morbid obesity surgery
.
Surg Obes Relat Dis
.
2007
Jul-Aug
;
3
(
4
):
456
60
.
[PubMed]
1550-7289
88.
Coupaye
M
,
Calabrese
D
,
Sami
O
,
Msika
S
,
Ledoux
S
.
Evaluation of incidence of cholelithiasis after bariatric surgery in subjects treated or not treated with ursodeoxycholic acid
.
Surg Obes Relat Dis
.
2017
Apr
;
13
(
4
):
681
5
.
[PubMed]
1550-7289
89.
Pizza
F
,
D’Antonio
D
,
Lucido
FS
,
Tolone
S
,
Del Genio
G
,
Dell’Isola
C
, et al
The Role of Ursodeoxycholic Acid (UDCA) in Cholelithiasis Management After One Anastomosis Gastric Bypass (OAGB) for Morbid Obesity: Results of a Monocentric Randomized Controlled Trial
.
Obes Surg
.
2020
Nov
;
30
(
11
):
4315
24
.
[PubMed]
0960-8923
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.